According to the Wisdom Financial News app, after a period of rating suspension, Citigroup has resumed its rating on Eli Lilly and Co (LLY.US). The bank rates it as a "buy" with a target price of $1060, citing a bullish outlook on the company's GLP-1 product line sales prospects, including its popular weight loss drug Zepbound, known as the "miracle weight loss drug", with its core component being tirzepatide.

Analyst Peter Verdult's bullish view is based on an upward revision of the forecast for tirzepatide (near to mid-term), which is named Mounjaro and Zepbound for the treatment of diabetes and obesity. The analyst reached this conclusion based on the latest sales reports of the drug, as well as prescription trends and guidance.

Furthermore, he also mentioned an increased expectation for orforglipron, an oral GLP-1 agonist currently undergoing weight loss studies.

As recently revealed in a medical event in Europe, analysts believe that Roche's oral GLP-1 candidate CT-996 is unlikely to challenge orforglipron due to the risks of increased heart rate and higher occurrence of nausea.

A recent study found that in a group of obese patients using Eli Lilly and Co's Mounjaro (core component tirzepatide, i.e., tirzepatide) for weight loss and diabetes treatment, the weight loss effect was significantly greater compared to patients using the drug Ozempic from novo-nordisk a/s (core component semaglutide, i.e., semaglutide) that has similar dual weight loss and diabetes treatment properties.

The above research is of great significance for the two pharmaceutical giants, 'Eli Lilly and Co' and 'Novo-nordisk a/s', which are forming a monopoly in the weight loss drug market. It may prompt more obese patients or people trying to lose weight through injections to turn to 'Eli Lilly and Co' instead of 'Novo-nordisk a/s', which may also have a boosting effect on 'Eli Lilly and Co's stock price.